BridgeMD
New treatment option for Chronic Coronary Syndrome
Official title Yangxinshi Tablet Intervention for Exercise Capacity in Patients With Chronic Coronary Syndrome
ClinicalTrials.gov ID: NCT06171061
What this study is testing
What is Yangxinshi tablet?
Yangxinshi tablet is an investigational medicine, given as a pill taken by mouth, being studied as a potential treatment for chronic coronary syndrome.
Also referred to as Yangxinshi.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study is a prospective, multicentre, randomized, open-label, blinded-endpoint clinical trial to evaluate the efficacy and safety of Yangxinshi tablets in the treatment of patients with chronic coronary syndrome (CCS).
- Phase 4: studies an already-approved treatment
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75
You may be able to join if
- age 18-75 years;
- CCS patients in stable condition and clearly diagnosed by coronary artery imaging (at least one vessel stenosis ≥ 50%): stable angina, ischaemic...
- moderately to severely limited exercise tolerance: the maximum 6MWD is \< 450 m, or the metabolic equivalent (MET) as measured by treadmill...
- voluntary participation and signing of informed consent.
You likely can't join if
- absolute or relative contraindications for the treadmill cardiopulmonary exercise test or 6-minute walk test (6MWT);
- serious primary diseases, mental diseases, or malignant tumours that affect lifespan;
- pregnancy, intended or suspected pregnancy, miscarriage, breastfeeding, or delivery in the last 6 months;
- people not suitable for this study in the opinion of the researchers, such as people who are participating in other drug clinical trials or...
The study team makes the final eligibility decision.
Where it's taking place
- Chongqing, Chongqing Municipality, China
- Zhengzhou, Henan, China
- Binzhou, Shandong, China
- Dezhou, Shandong, China
- Feicheng, Shandong, China
- Jinan, Shandong, China
- Liaocheng, Shandong, China
- Linqing, Shandong, China
- Linyi, Shandong, China
- Longkou, Shandong, China
- Qingdao, Shandong, China
- Taian, Shandong, China
- Tengzhou, Shandong, China
- Weifang, Shandong, China
- Yantai, Shandong, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Chongqing, Chongqing Municipality, China; Zhengzhou, Henan, China; Binzhou, Shandong, China; Dezhou, Shandong, China; Feicheng, Shandong, China; Jinan, Shandong, China and 9 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.